Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset
This article was originally published in The Pink Sheet Daily
Executive Summary
The planned purchase price of $11 billion, or $137 a share, an 89% premium over Pharmasset’s closing price on Nov. 18, is by far the highest ever paid for a clinical-stage biotech.